SLU begins clinical trial of Zika vaccine

The school is preparing for human trials.

As the Zika virus continues to spread, scientists are working to find a vaccine that can prevent infection.

Here in St. Louis, SLU's vaccine center will soon begin a safety trial of an investigational vaccine. The vaccine, called ZPIV, is made from Zika virus that has been inactivated to prevent infection.

The trial will be conducted at SLU's Center for Vaccine Development. A second trial will take place next year at a partnering research site in Puerto Rico.

SLU is recruiting 90 healthy adults ages 18 to 49 for the trial, which will be double-blind and placebo controlled. The volunteers will be followed for about one year after they are vaccinated.

If you'd like to learn more about vaccine research being conducted at SLU, call (314) 977-6333 or email


To find out more about Facebook commenting please read the
Conversation Guidelines and FAQs

Leave a Comment